222 related articles for article (PubMed ID: 35477830)
1. The roles and limitations of bevacizumab in the treatment of ovarian cancer.
Nakai H; Matsumura N
Int J Clin Oncol; 2022 Jul; 27(7):1120-1126. PubMed ID: 35477830
[TBL] [Abstract][Full Text] [Related]
2. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibition as frontline therapy in ovarian cancer.
Moore KN; Pothuri B; Monk B; Coleman RL
Clin Adv Hematol Oncol; 2020 Sep; 18(9):550-556. PubMed ID: 33006584
[TBL] [Abstract][Full Text] [Related]
4. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Park J; Lim MC; Lee JK; Jeong DH; Kim SI; Choi MC; Kim BG; Lee JY
J Gynecol Oncol; 2022 Mar; 33(2):e12. PubMed ID: 34910393
[TBL] [Abstract][Full Text] [Related]
5. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
6. Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
Pautier P; Motte-Rouge T; Lécuru F; Classe JM; Ferron G; Floquet A; Kurtz JE; Freyer G; Hardy-Bessard AC
Bull Cancer; 2021 Dec; 108(9S1):S22-S32. PubMed ID: 34955159
[TBL] [Abstract][Full Text] [Related]
7. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Klotz DM; Wimberger P
Arch Gynecol Obstet; 2020 Nov; 302(5):1087-1102. PubMed ID: 32833070
[TBL] [Abstract][Full Text] [Related]
8. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
9. Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma.
Sun L; Liu C; Li Y
Comput Math Methods Med; 2022; 2022():4600145. PubMed ID: 35720032
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibition in recurrent ovarian cancer.
Moore KN; Pothuri B; Monk B; Coleman RL
Clin Adv Hematol Oncol; 2020 Oct; 18(10):647-655. PubMed ID: 33201871
[TBL] [Abstract][Full Text] [Related]
11. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
12. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
13. Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs.
Nakai H; Matsumura N
Int J Clin Oncol; 2022 Jun; 27(6):1001-1012. PubMed ID: 35416600
[TBL] [Abstract][Full Text] [Related]
14. Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective.
Li N; Liu Q; Tian Y; Wu L
J Gynecol Oncol; 2022 Nov; 33(6):e86. PubMed ID: 36335989
[TBL] [Abstract][Full Text] [Related]
15. Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Selle F; Alexandre J; Prulhière K; Kalbacher E; Ray-Coquard I; Leary A;
Bull Cancer; 2021 Dec; 108(9S1):S5-S12. PubMed ID: 34955161
[TBL] [Abstract][Full Text] [Related]
16. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
17. The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza MR; Coleman RL; González-Martín A; Moore KN; Colombo N; Ray-Coquard I; Pignata S
Ann Oncol; 2020 Sep; 31(9):1148-1159. PubMed ID: 32569725
[TBL] [Abstract][Full Text] [Related]
18. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Cheng H; Yang J; Liu H; Xiang Y
Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
[TBL] [Abstract][Full Text] [Related]
19. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
20. Latest clinical evidence of maintenance therapy in ovarian cancer.
Walsh CS
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):15-21. PubMed ID: 31833941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]